Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

Serina Therapeutics, Inc. (NYSE American: SER) is approaching a consequential clinical milestone with SER-252, its long-acting POZ-apomorphine candidate for advanced Parkinson’s disease, now advancing into Cohort 2 of a registrational Phase 1b study. For many, the appeal is not simply that Serina is pursuing a large neurological indication; it is that the company is attempting to modernize a well-understood medicine with a delivery profile designed for the realities of advanced disease. On Thursday, September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET, Serina CEO Steve Ledger will discuss the program’s progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress” webinar, followed by a live Q&A. The efficient 30-minute format may be especially useful for many tracking one of biotech’s most durable value-creation formulas: familiar pharmacology, differentiated delivery, and a clinical path with identifiable milestones.

A Familiar Drug With an Unfamiliar Ambition

The investment case for Serina Therapeutics (NYSE American: SER) rests on a practical premise: Parkinson’s care has long needed better ways to sustain symptom control as disease advances. Parkinson’s disease is a progressive neurological disorder that affects dopamine-producing neurons; it is estimated to affect roughly 10 million people worldwide. While current treatments can improve symptoms, no approved therapy halts disease progression. For many patients, oral levodopa-based therapy can become less predictable over time, contributing to troublesome fluctuations between “ON” periods, when symptoms are better controlled, and “OFF” periods, when mobility and daily function can deteriorate. That makes sustained dopaminergic stimulation a clinically relevant goal, and turns drug delivery from a back-office detail into the main event. SER-252 is Serina’s attempt to address that delivery challenge. The investigational therapy pairs apomorphine, a recognized dopaminergic agent, with Serina’s proprietary POZ Platform™, which uses poly(2-oxazoline) polymer technology to extend and stabilize drug exposure. The target profile is a twice-weekly subcutaneous administration designed to provide prolonged apomorphine exposure without requiring a continuously worn infusion pump and tubing. In other words, Serina is not trying to convince the market that dopamine matters in Parkinson’s disease. That part of the syllabus is already well marked. It is trying to demonstrate that a better, less burdensome way to deliver a known therapy could matter greatly to patients, caregivers, clinicians, and, if the data cooperate, investors.

Cohort 1 Offers an Important Early Signal

In September, Serina reported that an independent Safety Monitoring Committee completed a blinded review of Cohort 1 in the ongoing Phase 1b registrational study and recommended that the program advance to Cohort 2. That is an important operational and clinical progression point for Serina. The early observations should be read with appropriate scientific discipline: the findings are preliminary, blinded, exploratory, and derived from a small cohort. Still, the disclosures were directionally encouraging.

• Cohort 1 evaluated the lowest dose in the single-ascending-dose portion of the trial.
• The company reported pharmacokinetic observations consistent with the sustained apomorphine exposure SER-252 was engineered to achieve.
• Blinded exploratory assessments included sustained periods of motor-function improvement in individual patients.
• Safety and tolerability findings supported dose escalation into Cohort 2.

For a platform-driven biotech company, that distinction is meaningful. The early readout is not intended to establish efficacy; rather, it begins to test whether the product is behaving as designed in people. In drug development, that can be the difference between a clever formulation deck and a clinically credible program.

Why the Delivery Proposition Matters

Advanced Parkinson’s disease is not a market where convenience is merely a nice-to-have. As symptoms progress, treatment routines can become more intensive, more invasive and more demanding for patients and care partners. Serina positions SER-252 as a potential next-generation approach to continuous dopaminergic stimulation. Its proposed twice-weekly subcutaneous treatment is designed to reduce the logistical burden of continuous infusion approaches, which can involve electronic pumps, tubing, regular management, and infusion-site issues. The company is also working with Enable Injections, a privately held drug-delivery company, on an on-body delivery concept designed for a short administration window. Serina says the envisioned system could be worn for roughly 10 to 20 minutes twice weekly, rather than requiring the constant companionship of a pump. In a therapeutic category where patients already have plenty of appointments, medications and movement challenges to manage, fewer wires may be more than a lifestyle upgrade—they may become a commercial advantage. The central clinical question, of course, remains whether SER-252 can deliver the pharmacokinetic consistency, safety, tolerability and patient-relevant motor benefits that would justify its differentiated product profile. But the commercial logic is straightforward: an advanced Parkinson’s treatment that aims to provide sustained exposure while reducing treatment friction could be compelling if it performs in later clinical and regulatory evaluation.

A Registrational Study With Defined Catalysts

Serina’s Phase 1b study is randomized, double-blind and placebo-controlled, with a single-ascending-dose portion comprising five cohorts of eight patients, followed by a multiple-ascending-dose component. The company is evaluating safety, tolerability and pharmacokinetics, while incorporating exploratory assessments such as MDS-UPDRS motor scores and structured measures of motor state. The trial is being conducted across the United States, Australia, South Korea and Taiwan. The near-term catalyst map is clear:

The study’s design and the company’s stated timeline give SER a relatively intelligible narrative for a clinical-stage biotechnology company: advance through dose escalation, protect trial integrity, report topline data in the first half of 2027, and determine whether the formulation’s intended advantages translate into a sufficiently differentiated clinical profile.

The Broader Platform Opportunity

SER-252 is the lead asset, but Serina’s longer-term proposition extends beyond a single Parkinson’s program. The company’s POZ Platform™ is designed to optimize the efficacy and safety profiles of multiple therapeutic modalities, including small molecules, RNA-based therapies and antibody-drug conjugates. That platform dimension matters because successful clinical validation of SER-252 could do more than advance one product candidate. It could provide evidence that Serina’s polymer-based approach can help reformulate and improve the practical use of therapeutics with known biological activity but suboptimal pharmacokinetics or tolerability. This is the elegant part of the strategy. Rather than attempting to discover every new molecule from scratch—a pursuit that has minted both fortunes and cautionary tales, Serina is pursuing a product-improvement model around delivery and exposure. It is a potentially capital-efficient concept, though its ultimate value will depend on clinical data, regulatory alignment, financing capacity and execution.

What Many May Want to Ask

The September 24 Tribe Public event provides a timely forum for investors to explore the clinical and commercial questions that will likely shape the next stage of the Serina Therapeutics (NYSE American: SER) story. Potential Q&A topics include:

• What specifically did the blinded Cohort 1 pharmacokinetic profile demonstrate about sustained apomorphine exposure?
• What are the key dose-escalation objectives and decision points for Cohort 2 and the remaining single-ascending-dose cohorts?
• How does Serina expect to differentiate SER-252 from existing or emerging advanced Parkinson’s delivery approaches?
• What evidence would most strongly support the company’s proposed convenience and treatment-burden advantages?
• What milestones should investors watch between now and the planned first-half 2027 topline single-ascending-dose data?
• How could validation of SER-252 inform the broader commercial potential of the POZ Platform™?

Questions may be submitted to research@tribepublic.com or through the Zoom chat during the event.

Bottom Line

Serina Therapeutics is at an early but increasingly tangible stage of building the SER-252 story. The company has moved beyond the abstract promise of a differentiated formulation and into a registrational clinical study that has cleared its first blinded safety review and begun advancing through dose escalation. For investors, Serina Therapeutics (NYSE American: SER) represents a data-driven, higher-risk biotechnology opportunity centered on an important unmet need in advanced Parkinson’s disease. The bullish thesis is not that the outcome is assured, it decidedly is not. It is that SER-252 is targeting a well-defined treatment problem with a rational delivery-based solution, an advancing clinical program and a milestone schedule that could keep the company in focus through 2027. The science still has work to do, as science tends to insist. But Serina’s early progress suggests that its attempt to make Parkinson’s treatment more continuous, and less mechanically complicated, is worth watching.

Event Details

Webinar: Tribe Public CEO Presentation and Q&A Event titled “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”
Date: Thursday, September 24, 2026
Time: 8:30 a.m. PT / 11:30 a.m. ET
Presenter: Steve Ledger, CEO, Serina Therapeutics, Inc. (NYSE American: SER)
Duration: Approximately 30 minutes, including a 5–10 minute live Q&A
Company website: Serina Therapeutics
Disclaimer: Tribe Public Disclaimers

The Sources

Sources

1. Serina Therapeutics Reports Cohort 1 Observations From SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2 Serina Therapeutics Investor Relations, September 9, 2026.
2. SER-252: POZ-Apomorphine for Advanced Parkinson’s Disease  Serina Therapeutics product-program overview, including the proposed twice-weekly subcutaneous delivery approach and POZ Platform™ rationale.
3. Serina Therapeutics Reports Second-Quarter 2026 Financial Results and Provides Business Updates  Serina Therapeutics Investor Relations, August 13, 2026. Includes SER-252 Phase 1b study design, enrollment update, and stated first-half 2027 topline-data target.
4. Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease  Serina Therapeutics Investor Relations, March 18, 2026.
5. Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease  Serina Therapeutics Investor Relations, February 19, 2026.
6. Serina Therapeutics Reports Full-Year 2025 Financial Results and Recent Business Highlights  Serina Therapeutics Investor Relations, March 25, 2026. Includes the company’s disclosure of FDA investigational new drug clearance and Phase 1b trial initiation for SER-252.
7. What Is Parkinson’s? Parkinson’s Foundation overview of Parkinson’s disease, its neurological basis, symptoms, and progression.
8. About Parkinson’s Disease  Parkinson’s Foundation fact sheet addressing Parkinson’s disease progression, dopamine-producing neurons, symptoms, and treatment context.
9. Serina Therapeutics Investor Relations  Corporate investor-relations resource for Serina Therapeutics, Inc. (NYSE American: SER), corporate news, filings, presentations, and clinical-program updates.
10. Tribe Public Disclaimers — Tribe Public event and content disclaimer page.